Genomic Downgraded to Neutral Zacks.com Recently, we downgraded Genomic Health (GHDX - Analyst Report), an oncology-based biotech company, to Neutral with a target price of $24.00. ... |
Subscribe to:
Post Comments (Atom)
Genomic Downgraded to Neutral Zacks.com Recently, we downgraded Genomic Health (GHDX - Analyst Report), an oncology-based biotech company, to Neutral with a target price of $24.00. ... |
No comments:
Post a Comment